In the next few years, the FDA will likely approve drug formulations containing psilocybin and MDMA. While there are still many unknowns concerning how psilocybin and MDMA-based drug therapies will be regulated, we believe that many of the same trends we have seen over the last few years in ketamine therapy will apply to these new drug therapies.
To that end, Harris Sliwoski attorneys recorded a free webinar on Tuesday, April 11 @ 10:00am PT in which they addressed the current regulatory landscape for ketamine, some potential bigger regulatory changes on the horizon, as well as some of the key issues for future FDA-approved psychedelic drug therapies.
Until then, more information can be found on our psychedelics page.
